激肽释放酶激肽系统与糖尿病肾病  

The kalUkrein.kinin system and diabetic nephropathy

作　　者：常宝成[1] 宋新荣[1] 

机构地区：[1]天津医科大学代谢病医院糖尿病肾病科,300070

出　　处：《国际内分泌代谢杂志》2011年第2期91-93,共3页International Journal of Endocrinology and Metabolism

摘　　要：激肽释放酶激肽系统（KKS）包括激肽释放酶、激肽原、激肽和激肽酶。肾脏含有KKS的所有组分。KKS通过影响系膜细胞增生、细胞外基质的合成与降解、足突细胞ZO-1蛋白的重排等而在糖尿病肾病的发生、发展中起重要作用。以KKS为靶向的糖尿病肾病干预策略包括胰激肽原酶、血管紧张素转换酶抑制剂、中性肽链内切酶抑制剂、血管肽酶抑制剂及缓激肽受体激动剂等。The kallikrein-kinin system （KKS） includes kallikrein, kininogen, kinin and kininase. All components of the KKS are expressed in the kidney. The KKS has been implicated in the development and progress of diabetic nephropathy by affecting the proliferation of mesangial cells, the synthesis and degradation of extraeellular matrix,the ZO-1 rearrangement of podncyte, and so on. The therapeutic strategies targeting the KKS for diabetic nephropathy include kallidinogenase, angiotensin-eonverting enzyme inhibitors, neutral endopeptidase inhibitors,vasopeptidase inhibitors and bradykinin receptor agonists.

关 键 词：激肽释放酶激肽系统 糖尿病肾病 血管紧张素转换酶抑制剂 

分 类 号：R587.2[医药卫生—内分泌]